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Abstract 
 
 
 
Background: The five-year survival of ovarian cancer has slowly increased but to 
date much of this has been due to the use of more lines of treatment rather than 
better first-line therapy. In this setting, there has been little improvement over the 
past fifteen years. The introduction of new treatments to extend time to first 
progression and overall survival remains a key objective of clinical research. 
 
Design: The focus of research in the previous decade has been on the incorporation 
of anti-angiogenic therapy or dose-dense scheduling of paclitaxel to improve 
outcome. The new trials being conducted build on the knowledge gained, and are 
focussing on two new areas of research, the use of PARP (poly-ADP ribose 
polymerase) inhibitors and immunotherapy. 
 
Results: Ongoing randomised trials using PARP inhibitors or immune checkpoint 
inhibits are reviewed and the potential benefits and challenges of using these agents 
are discussed.   
 
Conclusions: Improvements in outcome from some of the many open trials may 
present challenges; interpretation of the outcome data needs to be taken in the 
context of clinical benefit and a health-economic assessment. The latter is becoming 
ever-more important as the cost of trials with combinations of targeted therapy is 
very great 
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Introduction 
 
Surgery and chemotherapy, based on carboplatin and paclitaxel have been long 
established as the cornerstone for the primary management of ovarian cancer. The 
completeness of surgery is prognostic and this has led increasingly to the promotion 
of specialization and centralization. However, except in some cases of early stage 
ovarian cancer surgery alone is not curative; systemic therapy remains the most 
important component for the long-term survival of women with ovarian cancer. The 
three and five-year survival of ovarian cancer have improved over the last two 
decades and the question is to what extent has this been due to improvements in 
first-line therapy? Benefits from new first line treatments can be measured in several 
ways. Firstly, there may be a true increase in cure-rate, as measured by a reduced 
number of patients relapsing after first-line therapy. The key initial indicator that this 
might be occurring is an improvement in progression-free survival (PFS), or more 
specifically recurrence-free survival followed by an increase in overall survival (OS). 
However, improvements in PFS may not translate into an OS benefit if subsequent 
treatments have a differential effect, so as to annul differences seen in PFS in the 
first-line treatment. In contrast, there may be no direct benefit from new first line 
therapies on PFS but improvements in OS may arise through better use of 
subsequent lines of treatments. 
In this review, the impact on PFS and OS of first line treatments that have been 
studied over the last decade are discussed in relation to ongoing and new trials. 
These summarise current strategies to improve the outcome of first-line therapy in 
ovarian cancer. 
 
A decade of progress in the first line treatment of ovarian cancer? 
 
The publication in 2009 of GOG 182/ICON5, the largest prospective trial of first-line 
chemotherapy in ovarian cancer comparing four treatment arms of three cytotoxic 
drugs to three-weekly carboplatin and paclitaxel has served as a benchmark for 
future trials in ovarian cancer[1]. It showed that a third drug, added to three weekly 
carboplatin and paclitaxel did not increase the PFS, and that this combination was 
the standard of care for intravenous chemotherapy, and the control arm for future 
trials of first-line therapies. Where does the field stand, almost a decade later? There 
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have been two key strategies explored to improve the outcome of intravenous 
chemotherapy. The first moved away from adding new cytotoxic drugs and used the 
anti-VEGFA antibody, bevacizumab, the first molecularly targeted drug to be 
explored in first-line treatment of ovarian cancer. The second explored dose-
scheduling, increasing the dose-intensity of paclitaxel by giving it weekly rather than 
three-weekly in combination with carboplatin. 
 
Two large phase III trials of three weekly carboplatin and paclitaxel with or without 
bevacizumab were published in 2012 [2, 3] and it is important to consider the 
conclusions that can be drawn from these studies. Firstly, the addition of three 
weekly bevacizumab to chemotherapy and then continued as maintenance after 
chemotherapy significantly improved the PFS of women with newly diagnosed 
ovarian cancer who had undergone primary surgery. The benefit, measured as the 
improvement in median PFS was 3.8 months for GOG218 and the hazard ratio was 
0.717 (95% CI, 0.625 to 0.824; P<0.001). For ICON7 the median difference was 2.4 
months with a hazard ratio of 0.81 (95% CI, 0.70 to 0.94; P=0.004). The contribution 
of bevacizumab in both studies was broadly similar. It should be noted that the dose 
of bevacizumab GOG 218 was twice that in ICON7 (15 mg/kg versus 7.5mg/kg) and 
the duration of treatment was 15 months in the former study and 12 months in the 
latter. However, neither trial demonstrated an improvement in OS, so the 
interpretation of benefit depended on assessing the value extending the median 
PFS. Agreement about the beneficial value of the difference in PFS was not 
universal; the drug was approved for first-line therapy (15 mg/kg) by the European 
Medicines Agency, but not submitted to the Federal Drugs Agency as the overall 
benefit was believed to be too small to obtain approval. Some countries adopted the 
lower (unlicensed) ICON7 dose for therapy. This was done as the magnitude of 
overall benefit was similar to GOG218, but the duration of treatment was shorter, the 
cost was less. Furthermore, an analysis of patients in a ‘poorer prognosis’ group 
(sub-optimally debulked disease or stage IVdisease) showed not only a better 
improvement in PFS but also an improvement in OS. In ICON7 the median OS in 
this subgroup increased from 34·5 months [95% CI 32·0–37·0] to 39·3 months 
[37·0–41·7] with bevacizumab; using a restricted mean survival analysis (log-rank 
p=0·03)  [4]. By contrast the better prognosis group showed no PFS or OS benefit. 
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The added toxicity of bevacizumab (hypertension, proteinuria and fistula formation) 
was low and 17% patients discontinued bevacizumab due to adverse events. As the 
use of neoadjuvant chemotherapy is becoming more widely established, it is 
important to examine how bevacizumab might be integrated and to understand 
whether there is an increase in the preoperative response rate by adding 
bevacizumab. Whether this is the case is not entirely clear but a randomised non-
comparative phase II trial, ANTHALYA demonstrated a higher complete resection 
rate at IDS following 4 cycles of chemotherapy with bevacizumab (3 cycles) than in 
the reference group, without any significant increase in toxicity[5]. However, the 
different interpretation of data from bevacizumab trials has led to some uncertainty 
about the true value of the drug in first-line treatment, and there is variation in its use 
across the world. The 5th Ovarian Cancer Consensus Conference concluded that 
there was no consensus about the use of first-line bevacizumab but that it was an 
acceptable control arm for future clinical trials[6].  In many countries within Europe, 
bevacizumab is accepted as ‘the’ standard of care, and as the maximum benefit was 
seen at the time the drug was stopped, a large trial has followed GOG 218 
comparing 15 versus 30 months of treatment to see if the benefit – both PFS and OS 
could be extended further (NCT01462890). The results of this AGO-led ‘Boost’ trial, 
which has completed accrual are not yet known.  
 
As the results of bevacizumab trials in ovarian cancer began to emerge, other trials 
with anti-angiogenic agents were started. These included a trial with the oral VEGFR 
inhibitor, pazopanib given as 24 months maintenance after surgery and carboplatin 
and paclitaxel [7] and a trial with the triple angiokinase inhibitor, nintedanib given 
with chemotherapy and then as maintenance[8]. Both trials demonstrated that there 
was a statistically significant improvement in median PFS with the anti-angiogenic 
drugs, 5.6 months and 0.6 months respectively. However, netiher company has 
decided to take these results forward and submit either drug to the regulatory 
authorities for licensing, probably because interim analyses showed no benefit in 
OS. Neither drug has been taken forward for licensing in ovarian cancer. A third trial, 
TRINOVA-3 with trebananib (AMG386), an angiopoietin inhibitor in Stage III-IV 
ovarian cancer (NCT01493505) was terminated early due to lack of benefit. 
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In 2009, Katsumata and colleagues published the results of a Japanese randomised 
trial comparing the effect of dose-dense weekly or three weekly paclitaxel added to 
three weekly carboplatin in women with stage II-IV ovarian cancer. In this trial of 631 
patients, there was a significant improvement in median PFS in favour of weekly 
paclitaxel of 28.0 months (95% CI 22.3-35.4) compared with 17.2 months (95% CI 
15.7-21.1); (hazard ratio [HR] 0.71; 95% CI 0.58-0.88; p=0.0015 p=0.0015)[9]. An 
updated survival analysis in 2013 showed that the median OS was 100·5 months 
(95% CI 65·2-∞) in the dose-dense treatment group and 62·2 months (95% CI 52·1-
82·6) in the conventional treatment group (HR 0·79, 95% CI 0·63-0·99; 
p=0·039)[10]. These results were very provocative, as these differences in both PFS 
and OS were the largest that had been seen in randomised trials of first line therapy 
in ovarian cancer. As a result, three further phase III trials were initiated with the 
purpose of confirming the value of dose-dense paclitaxel. The first, GOG 262 used a 
similar design to the Japanese study but allowed the addition of three weekly 
bevacizumab to either arm. This was a patient/physician choice, and bevacizumab 
was adopted by 84% of the 692 patients in the trial. The results of GOG 262 showed 
no overall benefit of weekly paclitaxel, although a subset analysis of the patients who 
did not receive bevacizumab showed a PFS benefit similar to that seen in the 
Japanese trial[11]. A second international three-arm trial with over 1500 patients, 
ICON 8 is due to report later this year. In addition to a direct comparison of weekly 
and three weekly paclitaxel there is a third arm comparing the weekly administration 
of both carboplatin and paclitaxel with the standard three-weekly regimen. A weekly 
schedule of both drugs was used in a third study, MITO-7, a trial in more than 800 
patients.  The dose of paclitaxel, 60 mg/m2 was lower than in the Japanese study 
and carboplatin AUC2 was given weekly. There was no difference in PFS between 
the weekly and three weekly regimens[12].  In conclusion, apart from the Japanese 
trial, there has not yet been any further evidence to demonstrate a significant benefit 
of weekly paclitaxel.  
 
Is intraperitoneal therapy still an option to consider? 
 
There is probably no area in the field of therapeutics of ovarian cancer that has 
generated more controversy than the results of intraperitoneal therapy. The topic is 
discussed in detail elsewhere and is mentioned here only because it remains an 
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unresolved issue, and therefore a topic that needs to be considered in designing new 
trials for the treatment of ovarian cancer. The most recently reported randomised 
study, GOG 252 compared intravenous carboplatin and paclitaxel to two 
intraperitoneal regimens; one contained intraperitoneal carboplatin and the other 
intraperitoneal cisplatin and paclitaxel. The dose of intraperitoneal cisplatin was 75 
mg/m2, lower than the dose used in the previous trial, GOG 172[13]. Bevacizumab 
was used in all three arms. The trial failed to show any difference in PFS between 
the three treatment arms [14]. The results of an ongoing Japanese Gynecologic 
Oncology Group trial, iPocc comparing intravenous and intraperitoneal carboplatin 
are still awaited (NCT01506856). Even though the long-term follow up of GOG172, 
intraperitoneal cisplatin and paclitaxel continues to show a survival benefit at 10 
years[15] there is currently little global enthusiasm for developing new trials of 
intraperitoneal therapy. Perhaps the key reason for this lies with the expectation that 
novel molecular therapies will demonstrate much larger benefits than new trials with 
intraperitoneal therapy. 
 
Novel targeting approaches to first-line treatment of ovarian cancer 
 
Research into the treatment of recurrent ovarian cancer over the last decade has 
identified two new approaches that could potentially have a significant impact on 
first-line treatment. The first involves the use of PARP inhibitors, drugs that inhibit 
poly-ADP ribose polymerase, an important enzyme involved in the repair of DNA 
single-strand breaks. PARP inhibitors are oral agents that have been shown to 
prolong significantly PFS in patients with mutations in a BRCA gene.  Cells with a 
BRCA mutation have impaired repair of DNA double-strand breaks by homologous 
DNA recombination (HR), and rely on PARP activation to repair DNA damage. In 
these cells inhibition of PARP leads to cell death by a process called synthetic 
lethality. It has been estimated that 30-50 % of high grade serous tumours may be 
susceptible to PARP inhibitors due to mutations in other HR repair genes, or 
inhibition of BRCA function due, for example to DNA methylation[16, 17]. There is 
now good evidence that PARP inhibitors, such as olaparib, niraparib or rucaparib 
have a much wider spectrum of activity in high grade tumours which is broadly 
correlated with the empirically derived ‘platinum-sensitivity’. It may be possible to 
enhance the activity of PARP inhibitors further by combining them with anti-
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angiogenic drugs. This was demonstrated in a study by Liu and colleagues[18], who 
compared the activity of olaparib with a combination of olaparib and cediranib, an 
oral VGFR tyrosine kinase inhibitor in women with platinum-sensitive ovarian cancer. 
The combination of olaparib and cediranib was more active than olaparib, and this 
difference was particularly marked in the subset of patients without a BRCA 
mutation. These findings support the hypothesis that inhibition of angiogenesis may 
enhance the degree of HR repair deficiency, making cells more susceptible to PARP 
inhibitors. The question now is whether PARP inhibitors, alone or in combination with 
other molecular targeted therapies will improve the outcome of first-line therapy. 
 
The second development has been in the field of immunotherapy, using immune 
checkpoint inhibitors. Studies in ovarian cancer have progressed more slowly than 
those in other solid tumours, and much of the current information is derived from 
single-arm phase II studies or ‘basket’ trials containing cohorts of ovarian cancer 
patients. Currently, it appears that the response rate to immune checkpoint inhibitors 
is around 10% but stabilisation of disease is seen in a larger proportion of patients, 
some of whom have a prolonged period of disease control. These results have 
appeared sufficiently promising to take forward first-line trials with immune 
checkpoint inhibitors. 
 
First-line PARP inhibitor trials  
 
Maintenance post-chemotherapy has evolved as a major strategy for using PARP 
inhibitors, led by the licencing of maintenance olaparib in platinum-sensitive relapsed 
BRCA-mutated high grade serous cancer in many countries[19]. This approach has 
been extended to first-line therapy in the SOLO1 trial (NCT01844986) in which 
olaparib 300mg daily or placebo is given for 2 years post partial or complete 
response to chemotherapy in patients with BRCA-mutated high grade serous or 
endometrioid ovarian, fallopian tube or primary peritoneal cancer. The trial has 
completed recruitment but the analysis, driven by the number of progression events 
has not yet occurred. A different approach has been adopted in the GOG 3005 trial, 
an international collaborative trial sponsored by Abbvie, using veliparib in 
combination with chemotherapy and then as maintenance. In this 3-arm trial patients 
receive carboplatin/paclitaxel with veliparib or placebo followed by veliparib 
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maintenance, switch to placebo maintenance or continuations of placebo 
maintenance (NCT02470585). The trial allows standard three-weekly or dose-dense 
paclitaxel but it does not include bevacizumab. The trial aims to recruit about 264 
patients with a BRCA mutation out of a total of about 1100 patients.  
 
In patients with recurrent ovarian cancer it has been clearly shown that PARP 
inhibitors have a wider spectrum of activity, beyond patients with a BRCA mutation 
[19, 20]. Furthermore, the emerging data of the benefit of adding cediranib to 
olaparib [18] has generated interest in developing further combination studies. Phase 
I data have shown that olaparib and bevacizumab can be combined [21], although it 
is not clear if the two drugs are additive. This has led to the PAOLA-1 trial 
(NCT02477644), a first-line ovarian cancer study in which olaparib maintenance is 
added to bevacizumab, a standard targeted therapy used in many European 
countries. This ongoing study, led by the French GINECO group will randomise 612 
patients without progression following initial treatment with chemotherapy and 
bevacizumab to the addition of maintenance olaparib, 300mg daily for 24 months or 
placebo to standard-dose bevacizumab given for 15 months in total. The trial has 
almost completed recruitment. Following the recent publication of the NOVA trial with 
niraparib in recurrent ovarian cancer patients[20] a first-line maintenance trial has 
been launched in any patient with a stage II-IV high-grade tumour and partial or 
complete response to surgery and chemotherapy. The PRIMA trial (NCT02655016) 
will randomise 330 patients 2:1 to niraparib or placebo maintenance until progression 
or toxicity. 
 
Trials with immune checkpoint inhibitors 
 
In this fast-moving area of clinical cancer research, inhibitors of PD-1 and PDL-1 are 
now being evaluated in the first-line treatment of ovarian cancer. Following the small 
but encouraging results of nivolumab in recurrent ovarian cancer[22], publicly 
presented, but unpublished similar data with avelumab[23], the fully human IgG1 
antibody that specifically targets and blocks PD-L1, the ligand for PD-1 receptor,  
has led to an international first-line ovarian cancer trial. In JAVELIN 100 
(NCT02718417) , patients with stage III-IV ovarian cancer are randomised to one of 
three arms; avelumab maintenance, 10mg/kg two-weekly, placebo, or avelumab with 
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chemotherapy (avelumab 3-weekly) and then as two-weekly maintenance for 2 
years. The trial, which is currently recruiting permits weekly or three weekly 
paclitaxel, and it also allows neoadjuvant chemotherapy. However, it does not 
include bevacizumab, and in some countries, this has been felt to be a draw-back in 
the design, which otherwise accommodates broad-ranging real-world practice. More 
recently, the ENGOT and GOG partners group in collaboration with Roche have 
launched IMagyn50, a trial that includes bevacizumab and atezolizumab, an IgG1 
antibody targeting PDL-1 (NCT03038100). In this study patients with stage II-IV 
ovarian cancer are treated with standard three-weekly carboplatin/paclitaxel and 
bevacizumab with either atezolizumab or placebo added during the chemotherapy 
phase and as maintenance for up to 22 three-weekly cycles. The trial also allows a 
cohort of patients treated with neoadjuvant chemotherapy. Notwithstanding the 
absence of results from these studies discussions are being held about combining 
checkpoint inhibitors with PARP inhibitors. Early data in ovarian cancer with 
durvalumab and olaparib in heavily pretreated women are encouraging[24]. 
Collaborations will be required between companies, as there are several PARP and 
immune checkpoint inhibitors that could be paired up for such studies. The challenge 
is to select a design that not only optimises the combination but builds on as yet 
unknown results from ongoing trials with both agents, with or without the inclusion of 
bevacizumab. 
 
Evaluation of the results of first line trials in ovarian cancer 
 
Whilst the design of trials becomes more complex with increasing numbers of drugs, 
there are still fundamental issues relating to the assessment of outcome. These have 
recently been addressed in the 5th Ovarian Cancer Consensus Meeting. Whilst OS 
continues to be the ‘gold-standard’ for outcome it is recognised that demonstration of 
an increase in OS is not often achievable. Multiple post-progression therapies would 
require an (uneconomically) large sample size to demonstrate a relatively small OS 
improvement. Furthermore, with a long post-progression survival it would take many 
years for OS differences to emerge, and this can have a negative effect on financial 
investment in new drug development. In the consensus meeting it was concluded 
that PFS remains an acceptable primary endpoint but OS should be a secondary 
endpoint, and other endpoints such as patient-reported outcomes and other Quality 
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of Life indicators, time to first- or second-subsequent therapy (PFS2) should be 
included[6]. It was also acknowledged that several regimens can be used as 
‘controls’; three weekly carboplatin and paclitaxel remains the standard, but other 
regimens for which at least one randomised trial has shown superiority could be 
used, provided that the trial including such alternative regimens was stratified. The 
strategies being developed are complex and overlap, often employing more than one 
molecular targeting agent (TABLE). It will not be long before trials emerge that will 
combine three molecular targeted therapies- anti-angiogenic agents, inhibitors of 
PARP and immune checkpoints in the same trial. 
 
Concluding remarks 
 
As in many areas of clinical cancer research, many new molecularly targeted drugs 
are now showing activity in ovarian cancer. Whilst initial studies are performed in 
patients with recurrent disease, the impetus for developing these new therapeutic 
agents lies in finding better initial treatments for ovarian cancer. An increase in the 
rate of cure is the ultimate aim, but novel treatments that fail to do this may 
nevertheless significantly prolong the time before second line therapies are needed, 
and with big gains in PFS, differences in OS may emerge. Until the most recent trials 
with inhibitors of PARP or immune checkpoint pathways began, there had only been 
a modest improvement in PFS with molecularly targeted drugs, such as 
bevacizumab. The pace of development of these novel trials is fast, which partly is a 
reflection on the speed of development of these new agents and also commercial 
competition for the potential financial gains. The risks are that new trials are being 
launched ahead of results of some of the ongoing or recently completed trials, and 
this can pose challenges for the design of new studies. With the exception of trials in 
BRCAmut tumours, none of the studies use markers known to be predictive of 
outcome, and cannot currently be claimed to represent personalised therapies. 
However, the potential benefit of these new agents for patients could be 
considerable, and recruitment to these studies has not been problematic. But each 
new drug is expensive and the introduction of combinations of novel targeted agents 
in the large first-line population could pose major financial burdens on healthcare 
providers. It is becoming increasingly important to consider the cost-benefit of 
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therapy and good quality health economic assessments are needed to support a 
scientific evidence-base.  
 
 
 
Table: Ongoing phase III first-line trials in ovarian cancer with targeted agents 
 
 Trial Number Anti-
angiogenic 
drug 
PARP 
inhibitor 
Immune 
checkpoint 
inhibitor 
Type 
Boost (AGO) NCT01462890 bevacizumab   15 v 30 months 
bevacizumab 
maintenance 
GOG3005 
(Abbvie) 
NCT02470585  veliparib  3-arm chemotherapy with 
veliparib and veliparib 
maintenance 
PAOLA-1 
(GINECO) 
NCT02477644 bevacizumab olaparib  olaparib maintenance 
added to bevacizumab 
SOLO-1 
(AstraZeneca) 
NCT01844986  olaparib  olaparib maintenance in 
BRCAmut ovarian cancer 
PRIMA 
(Tesaro) 
NCT02655016  niraparib  Niraparib maintenance 
JAVELIN 100 
(Pfizer) 
NCT02718417   avelumab avelumab maintenance 
and avelumab with 
chemotherapy and 
maintenance 
IMagyn50 
(Roche) 
NCT03038100 bevacizumab  atezolizumab atezolizumab 
maintenance added to 
bevacizumab 
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